Pancreatology最新文献_第5页

Patient-derived organoids from pancreatic cancer after pancreatectomy: Feasibility and organoid take rate in treatment-naïve periampullary tumors. 胰腺切除术后胰腺癌患者来源的类器官：treatment-naïve壶腹周围肿瘤的可行性和类器官占用率。

IF 2.8 2区医学

Pancreatology Pub Date : 2024-12-26 DOI: 10.1016/j.pan.2024.12.018

Marcus T T Roalsø, Marina Alexeeva, Celine Oanæs, Martin Watson, Dordi Lea, Claudia Zaharia, Hanne R Hagland, Kjetil Søreide

{"title":"Patient-derived organoids from pancreatic cancer after pancreatectomy: Feasibility and organoid take rate in treatment-naïve periampullary tumors.","authors":"Marcus T T Roalsø, Marina Alexeeva, Celine Oanæs, Martin Watson, Dordi Lea, Claudia Zaharia, Hanne R Hagland, Kjetil Søreide","doi":"10.1016/j.pan.2024.12.018","DOIUrl":"https://doi.org/10.1016/j.pan.2024.12.018","url":null,"abstract":"Background/objective: Patient-derived organoids (PDOs) have emerged as essential for ex vivo modelling for pancreatic cancer (PDAC) but reports on efficacy and organoid take rate are scarce. This study aimed to assess the feasibility of establishing PDOs from resected specimens in periampullary tumors.Methods: Patients undergoing surgery for suspected periampullary cancer were included. PDO protocol amendments were tested, with organoid take rate as outcome measure. Samples from resected specimens were processed and expanded per protocol. Pooled estimate of take rates of PDOs in PDAC was derived from literature search.Results: 23 specimens were available for PDO, of which 10 were PDAC. In 15 patients other histopathology was found: neuroendocrine tumors (NET; n = 2), neuroendocrine carcinoma (NEC; n = 1), intraductal papillary mucinous neoplasm (IPMN; n = 4), distal cholangiocarcinoma (dCCA; n = 1), ampullary carcinoma (n = 1), duodenal carcinoma (n = 1), intra-ampullary papillary tubular neoplasm (IAPN; n = 1), indeterminate PDAC/ampullary carcinoma(n = 1), and one patient with chronic inflammation/fibrosis. Organoid cultures were grown from 7 of 10 (70 %) PDAC, 1 dCCA, 1 NEC, 1 duodenal carcinoma, 1 indeterminate tumor type and 1 ampullary carcinoma (i.e. 12/18; 66.7 % across periampullary cancers). Overall take rate of PDOs was 12 of 23 (52.2 %) for all tumors. A pooled mean estimate PDO take rate of 62.3 % (95 % CI:54.8-69.3 %) was reported across available studies in the literature.Conclusion: In the current study, we found that PDOs could be established from resected pancreatic tumors in over half of resected periampullary tumors, and highest in PDACs. As such, generating a pancreatic cancer PDO biobank for translational research was feasible after cryopreservation.","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Subclinical pancreatic exocrine insufficiency is associated with osteopathy in patients with chronic pancreatitis: Implications for management. 慢性胰腺炎患者的亚临床胰腺外分泌功能不全与骨病相关：对管理的影响。

IF 2.8 2区医学

Pancreatology Pub Date : 2024-12-25 DOI: 10.1016/j.pan.2024.12.017

Mehul Gupta, Shallu Midha, Vikas Sachdeva, Jairam Singh, Shivam Pandey, Chetanya Mittal, Varun Teja, Tanmay Vajpai, Anugrah Dhooria, Nikhil Tandon, Soumya Jagannath, Pramod Kumar Garg

{"title":"Subclinical pancreatic exocrine insufficiency is associated with osteopathy in patients with chronic pancreatitis: Implications for management.","authors":"Mehul Gupta, Shallu Midha, Vikas Sachdeva, Jairam Singh, Shivam Pandey, Chetanya Mittal, Varun Teja, Tanmay Vajpai, Anugrah Dhooria, Nikhil Tandon, Soumya Jagannath, Pramod Kumar Garg","doi":"10.1016/j.pan.2024.12.017","DOIUrl":"https://doi.org/10.1016/j.pan.2024.12.017","url":null,"abstract":"Background and aims: Patients with chronic pancreatitis (CP) may develop pancreatic exocrine insufficiency (PEI) but data regarding subclinical PEI are scarce. Our objective was to detect subclinical PEI in patients with CP and its functional consequences.Methods: We prospectively included patients with CP from April 2018-December 2021. Mild PEI and severe PEI were diagnosed if fecal elastase (FE) was 100-200 μg/g and <100 μg/g stool respectively. Vitamin levels and DEXA scan were done to assess functional consequences of PEI. Presence of subclinical PEI in CP (low FE-1 but without steatorrhea) with consequent osteopathy was the primary outcome.Results: Of 120 patients with CP, subclinical PEI (low FE-1 but no steatorrhea) was present in 84/120(70%) patients: 6/8(75%) in early CP, 41/53(77%) in definite CP and 37/55(67.2%) in advanced CP. Overall, 72.1% patients had osteopathy including 53(62%) among patients with subclinical PEI. There was no difference in osteopathy between subclinical and severe PEI. Patients with severe PEI had lower vitamin A levels as compared to mild PEI and no PEI patients [1.3 ± 0.5 mg/ml vs. 1.7 ± 0.6 mg/ml vs. 1.8 ± 0.5 mg/ml; p = 0.04]. There was no difference in vitamin D levels. Osteopathy was present in 40/56 (71.4%) in advanced, 26/56 (46.4%) in definite and 2/8 (25%) in early CP patients (p = 0.09). On multivariable analysis, patients with advanced CP had the higher risk of osteopathy (odds ratio 7.6, 95% CI 1.9-29.7).Conclusions: Subclinical PEI was present even in early CP with increased risk of osteopathy and fat-soluble vitamin deficiency.","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Time between pancreatic cancer diagnosis and treatment initiation and survival in the U.S. Military Health System. 在美国军事卫生系统胰腺癌诊断和治疗开始和生存之间的时间。

IF 2.8 2区医学

Pancreatology Pub Date : 2024-12-24 DOI: 10.1016/j.pan.2024.12.015

Yvonne L Eaglehouse, Sarah Darmon, Amie B Park, Craig D Shriver, Kangmin Zhu

{"title":"Time between pancreatic cancer diagnosis and treatment initiation and survival in the U.S. Military Health System.","authors":"Yvonne L Eaglehouse, Sarah Darmon, Amie B Park, Craig D Shriver, Kangmin Zhu","doi":"10.1016/j.pan.2024.12.015","DOIUrl":"https://doi.org/10.1016/j.pan.2024.12.015","url":null,"abstract":"Background: Pancreatic cancer has a high case fatality and treatment is known to improve survival. It is unknown whether the time between diagnosis and treatment initiation (time-to-treatment) is related to survival. Access to medical care may influence both treatment receipt and timing. We examined the relationship between time-to-treatment and survival among patients with pancreatic adenocarcinoma treated in the equal access Military Health System.Methods: We used the MilCanEpi database to study a cohort of 806 men and women who were diagnosed with stage I-IV pancreatic adenocarcinoma between 1998 and 2014 and received either surgery or chemotherapy as primary treatment. Time-to-treatment in relation to overall survival was examined in multivariable time-dependent Cox regression models.Results: Overall, median time-to-treatment was 3 weeks and 95 % of patients received treatment within 12 weeks. Time-to-treatment >6 weeks was associated with a statistically significant lower risk of death (AHR = 0.77, 95 % CI = 0.61-0.98) compared to time-to-treatment <3 weeks. Analysis by the first treatment type showed that time-to-surgery was not associated with survival among those receiving upfront surgery. Time-to-chemotherapy of >6 weeks was associated with reduced risks of death compared to <3 weeks (AHR = 0.62, 95 % CI = 0.48-0.80) for patients receiving primary chemotherapy.Conclusions: Our data suggests that longer time-to-treatment, especially among patients with chemotherapy, was associated with lower risk of death among patients with pancreatic adenocarcinoma who received treatment. Further research is needed to understand the association of intervals along the whole cancer spectrum (e.g., presentation, diagnosis, treatment) and longer treatment intervals (i.e., >12 weeks) with survival.","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endoscopic ultrasound is useful for the risk stratification of mucinous pancreatic cystic lesions: A long-term prospective study. 内镜超声对胰腺粘液性囊性病变的风险分层是有用的：一项长期前瞻性研究。

IF 2.8 2区医学

Pancreatology Pub Date : 2024-12-15 DOI: 10.1016/j.pan.2024.12.006

Sahar Wesali, Antonio Molinaro, Björn Lindkvist, Per Hedenström, Riadh Sadik

{"title":"Endoscopic ultrasound is useful for the risk stratification of mucinous pancreatic cystic lesions: A long-term prospective study.","authors":"Sahar Wesali, Antonio Molinaro, Björn Lindkvist, Per Hedenström, Riadh Sadik","doi":"10.1016/j.pan.2024.12.006","DOIUrl":"https://doi.org/10.1016/j.pan.2024.12.006","url":null,"abstract":"Objectives: The aims of this prospective observational study were to test worrisome features on endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) as a stratification tool in patients with mucinous pancreatic cystic lesions (PCLs), and to assess these patients' long-term risk of adenocarcinoma and mortality.Methods: Patients with suspected PCLs on cross-sectional imaging who underwent EUS-FNA at Sahlgrenska University Hospital between February 2007 and February 2018 were consecutively enrolled. The main inclusion criterion was the final diagnosis of a mucinous PCL. The results from EUS-FNA were analyzed in the context of outcome gathered from medical records of follow-up until February 2021.Results: Of 334 patients undergoing EUS-FNA, 171 (51 %) had a final diagnosis of a mucinous PCL. 29/171 (17 %) patients were diagnosed with HGD or adenocarcinoma <6 months after EUS-FNA, with 28/29 (97 %) patients having at least one worrisome feature on EUS-FNA. A solid component in mucinous PCLs on EUS was independently associated with the presence of HGD or adenocarcinoma (OR 23.6, 95 % CI 6.1-91.6, p < .001). A total of 4/142 (3 %) patients developed adenocarcinoma during the follow-up period (median = 61.4 months). Overall, in 80/82 (98 %) of the patients without worrisome features on EUS-FNA, HGD or adenocarcinoma was not detected. Six of the 21 (29 %) patients with HGD or adenocarcinoma who underwent surgery as initial management died from pancreatic cancer during follow-up.Conclusions: EUS-FNA is useful for the risk stratification of mucinous PCLs. The low incidence of adenocarcinoma over time after a negative EUS-FNA may allow for a less resource intensive surveillance strategy.","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142910064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends and impact of endoscopic ultrasound utilization for suspected intraductal papillary mucinous neoplasms. 内镜超声应用于疑似导管内乳头状粘液瘤的趋势和影响。

IF 2.8 2区医学

Pancreatology Pub Date : 2024-12-06 DOI: 10.1016/j.pan.2024.12.001

Lillian Wang, Priyanka Vatsavayi, Shounak Majumder, Ferga C Gleeson, Elizabeth Rajan, Barham K Abu Dayyeh, Andrew C Storm, Shifa Umar, Saran T Velaga, William S Harmsen, Santhi S Vege, Vinay Chandrasekhara

{"title":"Trends and impact of endoscopic ultrasound utilization for suspected intraductal papillary mucinous neoplasms.","authors":"Lillian Wang, Priyanka Vatsavayi, Shounak Majumder, Ferga C Gleeson, Elizabeth Rajan, Barham K Abu Dayyeh, Andrew C Storm, Shifa Umar, Saran T Velaga, William S Harmsen, Santhi S Vege, Vinay Chandrasekhara","doi":"10.1016/j.pan.2024.12.001","DOIUrl":"https://doi.org/10.1016/j.pan.2024.12.001","url":null,"abstract":"Background: Multiple management guidelines for intraductal papillary mucinous neoplasms (IPMNs) have been published to improve risk stratification and resource utilization. This study aims to evaluate trends in endoscopic ultrasound (EUS) use and agreement between cross-sectional imaging and EUS for specific pancreas cystic lesion (PCL) features.Methods: This retrospective cohort study included consecutive adults undergoing EUS for suspected IPMN detected with cross-sectional imaging (CT/MRCP) between 2013 and 2015 (Cohort 1) and 2018-2020 (Cohort 2). Clinical, radiographic, EUS, cytologic, and outcomes data were collected. IPMN were defined as high-risk/worrisome (having any Fukuoka high risk (HR) or worrisome feature (WF)), low risk (cyst size 10-29.9 mm, without Fukuoka HR or WF), or very low risk (cyst size <10 mm, without Fukuoka HR or WF). Chi-square, Fisher's exact test, Wilcoxon rank-sum test and Kappa statistics were used. Impact of the COVID-19 pandemic was assessed via post-hoc sensitivity analysis.Results: Of 711 patients, 292 (41.1 %) were in Cohort 1. More patients in Cohort 1 underwent EUS for non-high risk/non-worrisome PCL on pre-EUS imaging (65.8 % vs. 54.9 %, P < 0.01). Good agreement between pre-EUS imaging and EUS for WF (84.1 %) and HR (96.6 %) was seen. EUS-FNA impacted surveillance and surgical referral in 29.5 % (P = 0.51). Median surveillance duration was 917 days (IQR 367, 1439 days), during which pancreatic ductal adenocarcinoma (PDAC) was diagnosed in 7.5 % (P = 0.11).Conclusions: In this series EUS over-utilization for low risk IPMN improved over time reflecting more conservative guidelines, without changing PDAC diagnosis rates. There was good agreement between cross-sectional imaging and EUS for specific PCL features.","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plasmacytoid dendritic cells reduce acinar cell regeneration via IL33 and IFNA in an autoimmune pancreatitis model

IF 2.8 2区医学

Pancreatology Pub Date : 2024-12-05 DOI: 10.1016/j.pan.2024.05.030

Elisabeth Orgler , Nicole Schreiner , Hellen Ishikawa-Ankerhold , Lisa Fahr , Georg Beyer , Julia Mayerle , Ivonne Regel

引用次数: 0

Characterization of the immune microenvironment of pancreatic ductal adenocarcinoma and its precursor lesions with deep learning

IF 2.8 2区医学

Pancreatology Pub Date : 2024-12-05 DOI: 10.1016/j.pan.2024.05.086

Manuel Michels , Lena Haeberle , Marie Schulte , Carolin Mueller , Sebastian Haensch , Martin Schlensog , Friederike Opitz , Irene Esposito

引用次数: 0

Minimal-invasive methods show more benefit compared to opioids for pain management in unresectable pancreatic cancer – systematic review and meta-analysis

IF 2.8 2区医学

Pancreatology Pub Date : 2024-12-05 DOI: 10.1016/j.pan.2024.05.064

Ioana-Irina Rezuș , Ioana Creangă-Murariu , Anett Rancz , Oghosa Clinton Ibude , Mahmoud Obeidat , Renata Papp , Daniel Sandor Veres , Bogdan-Ionel Tamba , Peter Hegyi , Brigitta Teutsch

引用次数: 0

Misfolding trypsinogen mutant causes chronic pancreatitis in a preclinical mouse model

IF 2.8 2区医学

Pancreatology Pub Date : 2024-12-05 DOI: 10.1016/j.pan.2024.05.018

Mate Sandor , Alexandra Demcsak , Balazs Csaba Nemeth , Miklos Sahin-Toth

引用次数: 0

Minimallyinvasive spleen-preserving distal pancreatectomy in obese patients: factors associated with clinically relevant pancreatic fistula

IF 2.8 2区医学

Pancreatology Pub Date : 2024-12-05 DOI: 10.1016/j.pan.2024.05.005

Fabio Ausania , Carolina González-Abós , Filippo Landi , Dp Collaborative Group , Luca Morelli , P. Cristoforo Giulianotti

引用次数: 0